This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1qur

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1qur.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1qur.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1qur| PDB=1qur | SCENE= }}
{{STRUCTURE_1qur| PDB=1qur | SCENE= }}
-
'''HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR'''
+
===HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR===
-
==Overview==
+
<!--
-
Two bivalent thrombin inhibitors were synthesized, which consist of a benzamidine-based active-site-blocking segment, a fibrinogen recognition exosite inhibitor and a peptidic linker connecting these fragments. BZA-1 hirulog contains an Nalpha-(2-naphthylsulfonyl)-S-3-amidinophenylalanyl-is onipecotic acid residue connected via the carboxyl group to the linker segment. The active-site-directed moiety of BZA-2 hirulog [Nalpha-(2-naphthylsulfonyl-glutamyl)-R-4-amidinophenylal anyl-piperid ide] was coupled to the linker via the side chain of the glutamic acid. Both BZA-hirulogs contain almost identical linker-exo site inhibitor parts, except for the substitution of a glycine as the first linker residue in BZA-1 hirulog by a gamma-amino butyric acid in BZA-2 hirulog, thus increasing flexibility and linker length by two additional atoms. BZA-1 hirulog showed moderate potency (Ki = 0. 50 +/- 0.14 nM), while BZA-2 hirulog was characterized as a slow, tight binding inhibitor of thrombin (Ki = 0.29 +/- 0.08 pM). The stability in human plasma of both analogs was strongly improved compared with hirulog-1. For BZA-2 hirulog a significantly reduced plasma clearance was observed after intravenous injection in rats compared with BZA-1 hirulog and hirulog-1. The X-ray structure of the BZA-2 hirulog in complex with human alpha-thrombin was solved and confirmed the expected bivalent binding mode.
+
The line below this paragraph, {{ABSTRACT_PUBMED_10504391}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 10504391 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_10504391}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Blood coagulation]]
[[Category: Blood coagulation]]
[[Category: Trypsin like serine protease]]
[[Category: Trypsin like serine protease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 06:43:43 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 20:42:27 2008''

Revision as of 17:42, 28 July 2008

Image:1qur.png

Template:STRUCTURE 1qur

HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR

Template:ABSTRACT PUBMED 10504391

About this Structure

1QUR is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines., Steinmetzer T, Renatus M, Kunzel S, Eichinger A, Bode W, Wikstrom P, Hauptmann J, Sturzebecher J, Eur J Biochem. 1999 Oct;265(2):598-605. PMID:10504391

Page seeded by OCA on Mon Jul 28 20:42:27 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1qur"
Personal tools